文献速递基础与转化研究临床试验与 GCP

靶向E7的TCR工程T细胞治疗转移性HPV相关上皮癌

TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.
PubMed 文献 · Nat Med · 2021-02-08

一项首次人体1期试验评估靶向HPV-16 E7的TCR工程T细胞治疗转移性HPV相关上皮癌,主要终点为最大耐受剂量。最大剂量1×10^11个工程T细胞未受毒性限制,12例中6例客观缓解,包括8例抗PD-1耐药者中4例缓解;基因组研究揭示抗原呈递和干扰素反应通路缺陷导致耐药。

要点

  • 靶向HPV-16 E7的TCR工程T细胞最大剂量1×10^11未达毒性上限。
  • 12例转移性HPV相关上皮癌中6例客观缓解,含抗PD-1耐药者。
  • 耐药机制涉及抗原呈递和干扰素反应通路缺陷。

核心结论

  • 工程T细胞可介导常见上皮癌的肿瘤消退。
  • 免疫编辑是细胞治疗及可能其他免疫治疗在晚期上皮癌中的疗效限制因素。

研究设计与样本

  • 首次人体1期临床试验(NCT02858310),靶向HPV-16 E7的TCR工程T细胞治疗转移性HPV相关上皮癌。
  • 主要终点为最大耐受剂量;细胞剂量未受毒性限制,最大剂量为1×10^11个工程T细胞。
  • 肿瘤反应采用RECIST指南评估。

主要发现

  • 12例患者中6例出现客观临床反应。
  • 8例抗PD-1耐药患者中4例出现客观临床反应。
  • 反应包括大块肿瘤广泛消退及部分患者多数肿瘤完全消退。
  • 基因组研究(含同一患者反应不一的肿瘤)揭示抗原呈递和干扰素反应通路关键组分缺陷导致耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genetically engineered T cell therapy can induce remarkable tumor responses in hematologic malignancies. However, it is not known if this type of therapy can be applied effectively to epithelial cancers, which account for 80-90% of human malignancies. We have conducted a first-in-human, phase 1 clinical trial of T cells engineered with a T cell receptor targeting HPV-16 E7 for the treatment of metastatic human papilloma virus-associated epithelial cancers (NCT02858310). The primary endpoint was maximum tolerated dose. Cell dose was not limited by toxicity with a maximum dose of 1 × 1011 engineered T cells administered. Tumor responses following treatment were evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) guidelines. Robust tumor regression was observed with objective clinical responses in 6 of 12 patients, including 4 of 8 patients with anti-PD-1 refractory disease. Responses included extensive regression of bulky tumors and complete regression of most tumors in some patients. Genomic studies, which included intra-patient tumors with dichotomous treatment responses, revealed resistance mechanisms from defects in critical components of the antigen presentation and interferon response pathways. These findings demonstrate that engineered T cells can mediate regression of common carcinomas, and they reveal immune editing as a constraint on the curative potential of cellular therapy and possibly other immunotherapies in advanced epithelial cancer.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Nagarsheth NB, Norberg SM, Sinkoe AL, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med. 2021. PMID: 33558725. doi:10.1038/s41591-020-01225-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。